Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development
Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics
Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales.
HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026.
'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.'
'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.'
About HMBD-002
HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system.
About Hummingbird Bioscience
Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
About Percheron Therapeutics Limited
Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected].
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Deregulation Price Catalyst Spurs Bank of America Stock (BAC) Bulls
Bank of America (BAC) is standing at the edge of a transformative moment. A wave of deregulation is about to sweep through the financial sector, promising to loosen the tight capital and compliance rules that have weighed on banks for years. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter For BAC, this could mean more cash to lend, fatter investment banking fees, and juicier shareholder returns. While the stock has climbed to new 52-week highs, it is still priced as a value play. Therefore, I'm Bullish on BAC stock. Unleashing Lending Power Through Deregulation Momentum is building around deregulation, with major banks like Bank of America (BAC) poised to benefit. Potential rollbacks to Basel III capital requirements could unlock billions by lowering reserve thresholds, giving BAC more room to lend. In Q1, the bank reported $14.44 billion in net interest income on its $2 trillion deposit base, and analysts suggest that a looser regulatory environment could increase this figure by 6–7% this year, meaningfully boosting earnings. At the same time, compliance costs—long a drag on profitability—may finally ease. BAC's recent removal from a consumer watchdog's oversight hints at a broader regulatory reprieve. If oversight continues to soften, the bank could not only lower expenses but also redirect capital toward growth areas like small business loans and mortgages. Capital Markets Ready to Roar Bank of America's investment banking and trading divisions stand to gain significantly from a potential wave of deregulation. Looser rules tend to drive M&A activity, IPOs, and market volatility—ideal conditions for BAC's Global Markets unit. In Q1, equities trading revenue surged 17% to a record $2.2 billion, and fixed income climbed 5% to $3.5 billion, as Main Street Data shows. While investment banking fees dipped 3% to $1.5 billion, reflecting a broader slowdown in U.S. M&A, CEO Alastair Borthwick pointed to a strengthening deal pipeline. A more business-friendly climate under the Trump administration could accelerate this recovery. Meanwhile, the ongoing market resilience, even amid geopolitical tensions, signals investor optimism regarding pro-growth policies. For BAC, that translates into more opportunities to capitalize on volatility. Should deregulation spark renewed corporate deal flow—or support BAC's push into digital assets, such as its proposed USD-backed stablecoin—the bank could unlock new revenue streams and deepen its market advantage. Shareholder Returns Set to Shine Deregulation could be a goldmine for BAC's shareholders as well. With less capital tied up, BAC can ramp up buybacks and dividends. In Q1, earnings rose 11% to $7.4 billion, backed by a robust Common Equity Tier 1 ratio of 11.8%, well above the 10.7% minimum. This gives BAC plenty of room to return capital if these ratio requirements go down. Today, it has a $0.26 quarterly dividend yield of 2.25%, which the company has grown for 11 straight years, with 16 years of dividend growth to boot, according to TipRanks data. Meanwhile, projected buybacks for the year reach $18 billion, screaming confidence. In fact, BAC trades at a buyback yield of 4.3% on recent repurchases, which, along with the dividend, form a blended yield of 6.5%. Not bad for a company expected to see notable growth in the near term. In the meantime, the payout ratio stands at just 28.4% this year's consensus EPS estimate of $3.66, so an acceleration in the rate of dividend hikes is indeed possible. A Bargain Hiding in Plain Sight At today's share price, BAC stock is trading at its 52-week highs, but in my view, it's still a steal. Consensus EPS estimates project 14% growth to $3.66 in 2025, followed by an acceleration to 17% growth to $4.25 in 2026. Yet, BAC trades at just 12.7x 2025 EPS, which is significantly below that of some of its competitors. For context, JPMorgan's (JPM) 15x and Wells Fargo's 13.5x multiples are higher, despite BAC outpacing their growth forecasts. Tariff fears and potential rate cuts (which could possibly shave $3.3 billion off net interest income if rates drop 100 basis points) could spook investors. However, BAC's strong wealth management inflows and trading gains suggest that the impact may not be as harsh on a consolidated basis. What is the Price Target for Bank of America? Wall Street's stance on Bank of America stock is quite bullish. As things stand, BAC carries a Strong Buy consensus based on 18 Buy and two Hold ratings in the past three months. BAC's average 12-month price target of $49.50 implies a potential upside of approximately 6%, suggesting that many analysts believe the stock could continue to rise despite trading just below 52-week highs. Deregulation Tailwinds Could Power Next Leg of BAC Growth Bank of America is approaching a pivotal moment, with potential deregulation poised to unlock fresh growth opportunities. Positioned to boost lending, energize its capital markets division, and enhance shareholder returns, BAC looks compelling—especially at just 12.7x earnings and with EPS expected to rise 14–17% in the near term. While macroeconomic risks, such as trade tensions and interest rate shifts, remain, the bank's strong balance sheet and diversified operations provide a solid foundation for continued performance and investor upside.
Business Insider
2 hours ago
- Business Insider
Why Is Plus Therapeutics Stock (PSTV) Up 100% Today?
Plus Therapeutics (PSTV) stock saw a huge rally on Wednesday as the clinical-stage pharmaceutical company received approval from the Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for REYOBIQ. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter This approval covers the use of REYOBIQ as a potential treatment for pediatric patients with supratentorial recurrent, refractory, or progressive high-grade glioma (HGG) and ependymoma. The company will conduct a clinical trial of this, with the U.S. Department of Defense providing a $3 million grant to fund the study. PSTV stock was up 103.69% in pre-market trading on Wednesday, following a 1.47% rally yesterday. However, the shares are down 83.74% year-to-date and have seen much volatility in 2025. This makes the stock a dangerous gambit not fit for risk-averse traders. Is Plus Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Plus Therapeutics is Strong Buy, based on three Buy and one Hold rating over the past three months. With that comes an average PSTV stock price target of $10, representing a potential 5,247.59% upside for the shares.
CNBC
3 hours ago
- CNBC
Gold rises as weaker dollar, Trump's Powell criticism fuel uncertainty
Gold prices edged higher on Thursday, lifted by a weaker dollar and growing uncertainty after reports suggested U.S. President Donald Trump had considered replacing Federal Reserve Chair Jerome Powell as early as September or October. The reports raised concerns over the future independence of the U.S. central bank, boosting demand for safe-haven bullion. Spot gold was up 0.2% at $3,339.20 per ounce, as of 0242 GMT. U.S. gold futures rose 0.3% to $3,353.10. The dollar .DXY fell to its lowest level since March 2022, making greenback-priced gold less expensive for overseas buyers. Powell told a U.S. Senate panel on Wednesday that while Trump's tariffs may cause a one-time price hike, the risk of persistent inflation is significant enough for the central bank to be cautious about further rate cuts. "Trump clearly wants a dovish Fed Chairman next time around, so the increased likelihood of an aggressive rate-cutting cycle is pinning down the USD," KCM Trade Chief Market Analyst Tim Waterer said. Bullion tends to do well during periods of uncertainty and in a low-interest-rate environment. On Wednesday, Trump called Powell "terrible" and said he is considering three or four candidates for the top Fed post. Meanwhile, The Wall Street Journal reported that Trump has even toyed with the idea of announcing Powell's potential successor by September or October. Markets are awaiting U.S. GDP print due later in the day, while also keeping a watch for data on Personal Consumption Expenditures (PCE) on Friday. "Gold is just basically treading water for the moment until we get a read on the next batch of U.S. macro data including GDP and core PCE," Waterer said. A ceasefire between Israel and Iran appeared to be holding on Wednesday as Trump, at a NATO summit, praised the swift end to the 12-day conflict and said he would seek a commitment from Iran to end its nuclear ambitions at talks next week. Spot silver edged up 0.2% to $36.36 per ounce, platinum firmed 2.3% to $1,385.38, while palladium surged 5.5% to $1,115.58.
